Promethera, LifeLiver deal

Promethera granted LifeLiver rights to cell therapies HepaStem and H2Stem to treat liver diseases in South Korea. The companies will jointly develop the products to treat non-alcoholic steatohepatitis (NASH) and acute-on-chronic liver failure (ACLF), and LifeLiver will commercialize them in South Korea. Promethera will also provide Heparesc to LifeLiver for use in its bioartificial liver system to treat chronic liver failure. Promethera declined to disclose financial terms, and LifeLiver did not respond to inquiries...